热门话题-FDA对一种罕见病药物下达临床暂停令后,Aardvark股价重挫

路透中文
May 15
热门话题-FDA对一种罕见病药物下达临床暂停令后,Aardvark股价重挫

5月15日 - ** 药物开发商Aardvark TherapeuticsAARD.O)的股价下跌26.5%,至4.95美元,结束了连续四天的上涨势头

** 该公司周四晚间表示 (link) 美国食品药品监督管理局(FDA)已对其用于治疗普拉德-威利综合征(Prader-Willi syndrome)相关极度饥饿症状的实验性药物ARD-101实施全面临床暂停

** 该公司此前曾于2月暂停患者招募和给药 (link),原因是健康志愿者在接受高于计划剂量的药物后出现了心脏相关副作用

** AARD表示正与FDA积极磋商以解决该问题,并计划审查试验数据以评估安全性、有效性及后续步骤

** BTIG表示:“缺乏具体的时间表使得我们目前难以看好AARD,在这些关键问题获得更明确的解答之前,我们将保持观望”

** Stifel表示:“对于这项从一开始就风险极高的试验,我们目前仍难以对此感到放心”

** 计入本次交易,AARD今年以来累计跌幅达62%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10